uncovering new cellular pathways and precursors in the development of lung adenocarcinoma, the most common type of lung cancer. These findings open the ... Genetic Signature May Predict Response ...

Genprex has entered an exclusive licensing agreement with the US University of Michigan for lung cancer therapy, Reqorsa.

Genprex (GNPX) announced it has entered into an exclusive license agreement with the University of Michigan, granting Genprex a worldwide, ...

Lung cancer treatment has witnessed a revolution in recent years, largely driven by the increasing understanding of genetics ...

You may experience a high white blood cell count with lung cancer due to infections. Medications, such as chemotherapy, may also affect your white blood cell count. Lung cancer begins with lung ...

Identifying gene mutations has paved the way for targeted lung cancer testing and therapies. For example, targeted drug treatment therapies are available, or in development, for the following gene ...

Alectinib is recommended, within its marketing authorisation, as an option for the adjuvant treatment of stage 1B (tumours 4 cm or larger) to 3A ALK-positive non-small-cell lung cancer (NSCLC) after ...

There is a simple discount patient access scheme for alectinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Ultra-sensitive monitors may one day routinely have the ability to detect lung cancer on someone's breath. A small-scale test using a prototype device has demonstrated it can accurately detect the ...